Sugi Predict

Sugi Predict / Compounds / SCHEMBL1338499

SCHEMBL1338499

SCHEMBL1338499

C/C(=C\N(C)C)C(=O)c1ccc2c(c1)c1cc(-c3ccc(Cl)cc3)c(=O)n(C)c1n2C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 7/20 0.36
▸ CNR2 P34972 7/20 0.36
▸ CYP11B1 P15538 2/20 0.34
▸ CYP11B2 P19099 2/20 0.34
▸ GABRA1 P14867 2/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ EGFR P00533 1/20 0.32
▸ ALOX5 P09917 1/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32
▸ ADRA2C P18825 1/20 0.32
▸ MAPK3 P27361 1/20 0.32
▸ OPRL1 P41146 1/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ SLC18A2 Q05940 1/20 0.32
▸ MAPK14 Q16539 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338500 1.00 CNR1 (0.36) CNR1CNR2CYP11B1CYP11B2GABRA1
SCHEMBL1339045 0.90 MAPT (0.33) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL1339044 0.90 MAPT (0.33) KDM4EMAPTCYP1A2CYP2C19MEN1
SCHEMBL1337006 0.89 CNR1 (0.37) CNR1CNR2GABRA1GABRG2GABRB3
SCHEMBL1337007 0.89 CNR1 (0.37) CNR1CNR2GABRA1GABRG2GABRB3
SCHEMBL1339005 0.84 ALDH1A1 (0.42) CNR1CNR2GABRA1GABRG2GABRB3
SCHEMBL1338900 0.83 MAPT (0.49) SMN1; SMN2MAPTALDH1A1CYP1A2HPGD
SCHEMBL1338903 0.83 MAPT (0.49) SMN1; SMN2MAPTALDH1A1CYP1A2HPGD
SCHEMBL1338158 0.81 GSK3B (0.43) CNR1CNR2GABRA1GABRG2GABRB3
SCHEMBL1337044 0.79 CXCR3 (0.39) CNR1CNR2GABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 CNR1 262/4885CNR2 299/4885CYP11B1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.